Welcome to Bayside Health | Alfred Care Group. More information about Bayside Health can be found at baysidehealth.org.au

Contact About Find a doctor Careers The Alfred Foundation For staff

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Clear filter

627 clinical trials found

Clinical trials

DREAMM7

DREAMM7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma – DREAMM 7 (NCT04246047)

Currently recruiting

Dren Bio DR-0201-AIM-001

A Phase 1, Open-label, Multiple Ascending Dose Basket Study to Evaluate the Safety and Activity of DR-0201 in Patients with Select Autoimmune Rheumatic Diseases (NCT06647069)

The DR-0201-AIM-001 study is designed to evaluate the safety and efficacy of DR-0201 in adult participants with lupus, primary Sjögren’s syndrome and/or scleroderma.
Participants receive trial medication via an infusion over 26 weeks at varying intervals.

Currently recruiting

DRESS

Assessing the role of mepolizumab in DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome: a pilot study (ACTRN12621001333808)

No longer recruiting

DRI19220

A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa [BRIGHTEN] (NCT07170917)

The purpose of this study is to assess the efficacy and safety of brivekimig in a dose-ranging study of participants with moderate to severe Hidradenitis Suppurativa (HS). Participants will be in the study for up to 60 weeks and have the option to enter a long-term extension study for an additional 52 weeks. The treatment will be administered via subcutaneous injection (small injection into the abdomen) every two weeks.

Currently recruiting

Duavive in PMD

Double-Blind Randomised Investigation of Bazedoxifene and conjugated estrogen for Depression in Menopausal Women (ACTRN12620001015932)

Currently recruiting

DUET-UC

A Phase 2b Randomized, Double-blind, Active- and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colitis (NCT05242484)

Currently recruiting

DZ2022B0002

A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT05824585)

Currently recruiting

E-nside INNER-B-APAC

INNER-B-APAC – Asian Pacific post-market clinical follow-up study in patients with thoracoabdominal aortic aneurysms treated with E-nside TAAA Multibranch Stent Graft System (NCT05954793)

Currently recruiting

E-TAN

A double-blinded randomised placebo-controlled trial of estradiol: investigating the effect on disordered eating symptoms of women with anorexia nervosa (ACTRN12623000897662)

Currently recruiting

ECMO-REHAB

A Randomised Controlled Trial of Early Rehabilitation in Patients on Extracorporeal Membrane Oxygenation (ECMO-Rehab) (NCT05003609)

No longer recruiting

EFC15951

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (NCT05405166)

Currently recruiting

EFC17559 [COAST-1]

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group, 3-arm, multinational, multicenter study to evaluate the efficacy and safety of amlitelimab monotherapy by subcutaneous injection in participants aged 18 years and older with moderate-to-severe atopic dermatitis (NCT06130566)

No longer recruiting

EFC17600

A Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel group 48-week extension study to evaluate the treatment response and safety of two amlitelimab dose regimens administered as monotherapy by subcutaneous injection in participants aged 12 years and older with moderate-to-severe atopic dermatitis (NCT06407934)

No longer recruiting

eFemoral

A Clinical Evaluation of the Efemoral Vascular Scaffold System [EVSS] for the Treatment of Patients with Symptomatic Peripheral Vascular Disease from Stenosis or Occlusion of the Femoropopliteal Artery (NCT04584632)

This trial is looking at a new treatment called the Efemoral Vascular Scaffold System (EVSS), a tiny dissolvable scaffold coated with medication that helps keep blood flowing in narrowed or blocked leg arteries. VSS is designed to support the artery while it heals and then gradually dissolve, leaving the vessel free to move naturally. This may improve circulation, reduce symptoms like leg pain when walking, and support long-term artery health.

Currently recruiting

EFFECT

Investigating the immunomodulatory and clinical effects of fermentable fibre intervention to reduce symptoms of Long COVID (ACTRN12624000356561)

Currently recruiting

ELEVATE-HFpEF

Randomized trial of ELEVATEd cardiac pacing rate for personalized treatment of Heart Failure with preserved Ejection Fraction [ELEVATE-HFpEF] (NCT06678841)

Currently recruiting

Eli-Lily I7P-MC-DSAF

A Phase 2b, Double-Blind, Placebo-Controlled Study to Evaluate Eltrekibart in Adult Participants with Moderate to Severe Hidradenitis Suppurativa (NCT06046729)

No longer recruiting

EMERALD-2

Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who are at high risk of reccurence after curative hepatic resection or ablation (NCT03847428)